Fjarde AP Fonden Fourth Swedish National Pension Fund Trims Position in Stryker Co. (NYSE:SYK)

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its stake in shares of Stryker Co. (NYSE:SYK) by 6.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 54,483 shares of the medical technology company’s stock after selling 3,600 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Stryker were worth $19,617,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of SYK. Private Advisor Group LLC raised its holdings in Stryker by 3.4% in the 3rd quarter. Private Advisor Group LLC now owns 15,967 shares of the medical technology company’s stock valued at $5,768,000 after buying an additional 526 shares during the period. Assenagon Asset Management S.A. raised its holdings in Stryker by 15.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after buying an additional 1,392 shares during the period. Global Trust Asset Management LLC purchased a new stake in Stryker in the 3rd quarter valued at about $69,000. DT Investment Partners LLC raised its holdings in Stryker by 114.3% in the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock valued at $49,000 after buying an additional 72 shares during the period. Finally, Trueblood Wealth Management LLC raised its holdings in Stryker by 7.6% in the 3rd quarter. Trueblood Wealth Management LLC now owns 2,841 shares of the medical technology company’s stock valued at $1,026,000 after buying an additional 200 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 1.0 %

Shares of NYSE:SYK opened at $382.59 on Friday. The stock’s 50-day moving average price is $378.07 and its two-hundred day moving average price is $368.99. The firm has a market cap of $145.99 billion, a price-to-earnings ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 earnings per share. On average, research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s payout ratio is 43.30%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. The Goldman Sachs Group boosted their price target on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. Evercore ISI boosted their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Stifel Nicolaus boosted their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Finally, Truist Financial boosted their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $422.15.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.